Clinical trials: Marijuana
Cannabis Withdrawal
Effect of PP-01 on Cannabis Withdrawal Syndrome
This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to…
- Trial name
- NCT05494437
- Testing
- PP-01 High Dose, PP-01 Low Dose, Nabilone
- Where
- 18 sites in United States
- Volunteers
- 234 people
- Sponsor
- PleoPharma, Inc.
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Substance Use Disorders, Addiction, Alcohol
Evaluating the Effectiveness of Mobile Self-guided Psychological Interventions to Reduce Relapse in Substance Use Disorder
The aim of the study is to evaluate the effectiveness of mobile interventions in reducing craving and lapses in patients diagnosed with Substance Use Disorder.
- Conditions
- Substance Use Disorders, Addiction, Alcohol, Addiction, Substance
- Trial name
- NCT05730504
- Testing
- Mobile app-based self-guided interventions
- Where
- Poland
- Volunteers
- 400 people
- Sponsor
- PredictWatch
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
Study to assess the effect of rifampicin, ketoconazole and omeprazole on the pharmacokinetics of a single dose of Sativex and to evaluate the safety of Sativex when given in combination with these other drugs.
- Conditions
- Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
- Trial name
- NCT01323465
- Testing
- Sativex and rifampicin, Sativex and ketoconazole, Sativex and omeprazole
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Acute Cannabis-induced CNS Depression
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to…
- Trial name
- NCT06017622
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Anebulo Pharmaceuticals
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Acute Brain Injury
Transcutaneous Pulse Oximetry Brain Monitoring Study (US)
This is a study of adult patients with a severe and sudden brain injury who have a drain placed in their brain to measure pressure.
- Trial name
- T-POT US (NCT06267131)
- Testing
- Brain Pulse Oximeter
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cyban Pty Ltd
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071988
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Impairment, Cannabis Intoxication
Eye Movement Tracking to Detect Impairment Due to Acute Cannabis Intoxication
The purpose of this study is to determine the accuracy of an impairment algorithm based on eye tracking while watching a short film clip, in comparison to a clinical reference standard of impairment.
- Trial name
- NCT04799093
- Testing
- EyeBOX
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Oculogica, Inc.
Parkinson Disease
Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms
Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.
- Trial name
- CBD-EP-2 (NCT06629389)
- Testing
- Cannabidiol 100 mg/ml, cannabidiol 300 mg/ml, Cannabidiol 400 mg/ml
- Where
- Argentina
- Volunteers
- 88 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Posttraumatic Stress Disorder
Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder
The purpose of this study is to evaluate the safety and efficacy of vaporized cannabis in participants with chronic, treatment-resistant posttraumatic stress disorder.
- Trial name
- NCT02517424
- Testing
- High THC/Low CBD Cannabis, High THC/High CBD Cannabis, Low THC/Low CBD Cannabis
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Tilray
Renal Insufficiency, Kidney Disease
A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.
The study aims to determine the pharmacokinetic (PK) profile of a single oromucosal dose of Sativex® (i.e. how the body absorbs, distributes, metabolises and excretes the drug) when subjects have severe renal impairment or end…
- Trial name
- NCT02325024
- Testing
- Sativex
- Volunteers
- healthy volunteers welcome
- Sponsor
- GW Pharmaceuticals Ltd
Spasticity, Multiple Sclerosis
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.
- Trial name
- NCT01868048
- Testing
- Sativex
- Sponsor
- GW Research Ltd
Pain, Peripheral Neuropathy
A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® in relieving neuropathic pain.
- Trial name
- NCT00713323
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 380 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Non-specific Low Back Pain
Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain
Randomized, open-label, parallel-group phase III trial to prove an additional benefit of the full-spectrum cannabis extract VER-01 over opioids in patients with chronic non-specific low back pain for whom drug treatment is…
- Trial name
- ELEVATE (NCT05610813)
- Testing
- VER-01, Opioid therapy
- Where
- 2 sites in Germany
- Volunteers
- 384 people
- Sponsor
- Vertanical GmbH
Hepatic Impairment
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
A Phase I open-label study to evaluate the pharmacokinetics (what the body does to a drug), safety and tolerability of a single dose of Sativex (containing 10.8 mg tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) in…
- Trial name
- NCT01887301
- Testing
- Sativex
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Autism, Autism Spectrum Disorder
Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism
The goal of this clinical trial is to determine whether cannabidiol (CBD, 28%) combined with terpenes and a small amount of THC (1%) can help reduce symptoms of autism, and to evaluate the safety of this treatment.
- Trial name
- TECA (NCT07199218)
- Testing
- Terpenes-Enriched CBD-Predominant Oil, Terpenes-Enriched CBD Oil (THC-Free)
- Where
- Israel
- Volunteers
- 78 people
- Sponsor
- Bazelet Nehushtan LtD.
Detrusor Overactivity, Multiple Sclerosis
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in reducing the daily number of episodes on incontinence.
- Trial name
- NCT00678795
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis
- Trial name
- NCT01599234
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Jazz Pharmaceuticals
Autistic Disorder
A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
This single center, double-blinded, randomized, placebo-controlled crossover trial will assess the efficacy and safety of extraction of cannabis flowers dissolved in olive oil (30% CBD and 1.5% Δ9-THC) vs.
- Trial name
- NCT05413187
- Testing
- Medical Grade Cannabis oil
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- TO Pharmaceuticals